AC   CVCL_V407
DR   cancercelllines; CVCL_V407
DR   Wikidata; Q54881809
RX   PubMed=21062933;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:114785; Erlotinib.
CC   Selected for resistance to: ChEBI; CHEBI:90197; PHA-665752.
CC   Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2236_2250del15); ClinVar=VCV000177620; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val218del (c.646_648GTG[2]) (c.652_654delGTG); ClinVar=VCV000634761; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2063 ! HCC827
SX   Female
AG   39Y
CA   Cancer cell line
DT   Created: 16-04-14; Last updated: 05-10-23; Version: 14
RX   PubMed=21062933; DOI=10.1158/1078-0432.CCR-10-1371;
RA   Suda K., Murakami I., Katayama T., Tomizawa K., Osada H., Sekido Y.,
RA   Maehara Y., Yatabe Y., Mitsudomi T.;
RT   "Reciprocal and complementary role of MET amplification and EGFR T790M
RT   mutation in acquired resistance to kinase inhibitors in lung cancer.";
RL   Clin. Cancer Res. 16:5489-5498(2010).